AK112
AK112 is a pharmaceutical drug with 35 clinical trials. Currently 23 active trials ongoing. Historical success rate of 87.5%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
15
Early Stage
15
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.5%
7 of 8 finished
12.5%
1 ended early
23
trials recruiting
35
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
AK112 in Advanced Non-Small Cell Lung Cancer
Clinical Trials (35)
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
AK112 in Advanced Non-Small Cell Lung Cancer
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
A Study of AK112 in Advanced Malignant Tumors
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 35